Lazertinib belongs to the first generation EGFR targeted therapy drug classification

Lazertinib is a third-generation epidermal growth factor receptor (EGFR) targeted therapy drug. It is mainly used to treat patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Its emergence mainly targets the resistance problems faced by early-generation and second-generation EGFR inhibitors, especially the T790M mutation. T790M mutation is the main reason why patients fail to treat traditional EGFR inhibitors. Lazertinib significantly improves the therapeutic effect by selectively inhibiting this mutant EGFR.

A key advantage of third-generation EGFR inhibitors is their ability to effectively recognize and bind the T790M mutation while less inhibiting wild-type EGFR, thereby reducing the occurrence of side effects. Lazertinib, as a representative of this class of drugs, exhibits higher selectivity and better safety. Compared with first-generation drugs such as gefitinib and erlotinib, lazertinib reduces common side effects such as rash and diarrhea, improving patient tolerance and quality of life.

In addition, lazertinib has excellent performance in penetrating the blood-brain barrier, giving it a clear advantage in treating EGFR mutation-positive lung cancer patients with brain metastases. Brain metastasis is a common complication of late-stage lung cancer. Many traditional EGFR inhibitors are difficult to effectively reach brain lesions. However, lazertinib can better enter the central nervous system, inhibit the growth of brain tumor cells, and delay the progression of brain metastasis.

In summary, lazertinib, as a third-generation EGFR targeted therapy, has the characteristics of strong pertinence, low side effects and significant efficacy in brain metastasis. Its clinical application not only improves treatment options for drug-resistant patients, but also brings better prognosis and quality of life to lung cancer patients, promoting the development of precision medicine for lung cancer.

Reference materials:https://www.drugs.com/donanemab.html